title: Involvement of P2Y receptors in pyridoxal-5'-phosphate-induced cardiac preconditioning.
abstract: Using an isolated non-working rat heart model, this study investigated the mechanisms of pharmacological pre-conditioning (PC) induced by P2Y receptor stimulation with pyridoxal-5'-phosphate (PLP). After 6-hydroxydopamine pretreatment and a 15-min stabilization period, isolated rat hearts were perfused for 25 min then subjected to 40 min of global ischemia and 30 min of reperfusion (I/R); exposed for 15 min to 0.05 microM PLP bracketed for 25 min with broad-spectrum P2 antagonists (suramin or PPADS) or with more specific P2Y antagonists (AMPalphaS or MRS2578), 1 microM each, followed by a 5-min PLP-free perfusion before I/R; treated during 25 min with either glybenclamide (GLY, 1 microM), 5-hydroxydecanoic acid (5-HD, 100 microM), U73122 (0.5 microM), H89 (1 microM), or KN93 (1 microM), with an infusion starting 5 min before PLP. The main endpoints were the rate-pressure product (RPP), creatine kinase (CK) release and area necrosis. Recovery of RPP, measured 5 min after reperfusion, was rapidly improved by PLP, blocked by the P2 antagonists, and decreased with the different inhibitors. Fifteen minutes after the end of ischemia, CK release reached maximal values in all groups. PLP provided significant protection, whereas the P2 antagonists, 5-HD, a mitochondrial selective K(ATP) antagonist and GLY a non-selective K(ATP) channel blocker, suppressed the protective effect on myocardial injury. The suppression of the cardioprotective effects of PLP by AMPalphaS, the PKA inhibitor (H89), and phospholipase C blocker (U73122) is in agreement with the P2Y11 receptor as a receptor for PLP-induced PC. The suppression of the cardioprotective effects of PLP by MRS2578 and U73122 is in agreement with the P2Y6 receptor as a receptor for PLP-induced PC. Pre-ischemic exposure to nanomolar concentrations of PLP is protective against I/R. P2Y11 and P2Y6 represents the most likely candidate receptors for PLP-induced cardiac PC.
authors.affiliation: Department of Pharmacology, E.A.3801, IFR53, Reims University Hospital 51, Rue Cognacq-Jay, 51095 Reims Cedex, France. herve.millart@univ-reims.fr
authors.forename: Hervé
authors.initials: H
authors.lastname: Millart
authors.forename: Loubna
authors.initials: L
authors.lastname: Alouane
authors.forename: Floriane
authors.initials: F
authors.lastname: Oszust
authors.forename: Stephane
authors.initials: S
authors.lastname: Chevallier
authors.forename: Arnaud
authors.initials: A
authors.lastname: Robinet
mesh_terms: D000818:Animals; D003402:Creatine Kinase / Q000187:drug effects / Q000378:metabolism; D004195:Disease Models, Animal; D019157:Ischemic Preconditioning, Myocardial / Q000379:methods*; D008297:Male; D015428:Myocardial Reperfusion Injury / Q000517:prevention & control*; D009336:Necrosis / Q000473:pathology; D011732:Pyridoxal Phosphate / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D018048:Receptors, Purinergic P2 / Q000187:drug effects* / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects
chemical_list: C109734:P2RY11 protein, human; D018048:Receptors, Purinergic P2; C099845:purinoceptor P2Y6; D011732:Pyridoxal Phosphate; D003402:Creatine Kinase